STAT+

    Second death in Chinese clinical trial rekindles debate on safety

    Last year, a little-known Chinese startup took center stage at the American Society for Gene and Cell Therapy annual convention in New Orleans.  Speaking before a sprawling conference hall for the presidential symposium, HuidaGene CEO Alvin Luk presented data from one of the world’s first trials to test if CRISPR gene editing could treat children…

    Read More
    HUTCHMED gains wider China drug coverage on NRDL, insurance

      Telix Pharmaceuticals updates Illuccix China trial, FDA plans

      Telix (ASX: TLX, NASDAQ: TLX) provided a precision medicine portfolio update on Dec 21, 2025 covering three PET imaging candidates. TLX591-CDx (Illuccix): Phase 3 China study (n=140) met its primary endpoint with overall patient-level PPV 94.8% (95% CI: 85.9%, 98.2%), region-level PPV 100% in prostate bed and non-bone metastases, and…

      Read More
      Jeff Bezos agrees with OpenAI’s Sam Altman: We’re in an AI bubble. But Amazon's founder says the benefits will be ‘gigantic’

      Jeff Bezos agrees with OpenAI’s Sam Altman: We’re in an AI bubble. But Amazon’s founder says the benefits will be ‘gigantic’

      Jeff Bezos joined Sam Altman in admitting the existence of an AI bubble—but Amazon’s founder sees upside. Recently, many AI-related companies have seen voracious optimism and spikes in valuations. In August, the OpenAI CEO told reporters the AI market was in a bubble. When bubbles happen, “smart people get overexcited about a kernel of truth,” Altman…

      Read More